NATH BIO (India) Financial Analysis

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:3em;padding-top: 40px;;'>NAT</div>
The current investor indifference towards the small price fluctuations of NATH BIO GENES IN may encourage investors to take a closer look at the entity as it closed today at a share price of 0.0 on very low momentum in trading volume. The company directors and management did not add any value to NATH BIO GENES investors in January. However, most investors can still diversify their portfolios with NATH BIO GENES IN to hedge your portfolio against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 0.0. The very small Stock volatility is a good signal to investors with longer term investment horizons. The NATH BIO GENES IN financial analysis interface makes it easy to digest most current publicly released information about NATH BIO as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analyze NATH BIO price relationship with some important fundamental indicators such as market cap and management efficiency. Additionally see Stocks Correlation.


The company has price-to-book ratio of 1.95. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. NATH BIO GENES had not issued any dividends in recent years. Nath BioGenes Limited engages in the production, processing, and marketing of hybrid and GM seeds in India. To find out more about N/A contact the company at 91 24 0237 6314 or learn more at http://www.nathbiogenes.com.


NATH BIO GENES is not yet fully synchronised with the market data
NATH BIO GENES has some characteristics of a very speculative penny stock
N/A has accumulated about 76.92 M in cash with (141.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.81.

Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.67 B.


The company has Profit Margin (PM) of 4.34 % which can be a sign that it executes well on its competitive strategies and has a good control over its expenditures. This is normal as compared to the sector avarege. Similarly, it shows Operating Margin (OM) of 9.44 % which suggests for every 100 dollars of sales it generated a net operating income of 0.09.

Management Efficiency

NATH BIO GENES has return on total asset (ROA) of 3.2 % which means that it generated profit of $3.2 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 4.92 % meaning that it generated $4.92 on every $100 dollars invested by stockholders.

NATH BIO Technical and Predictive Indicators

Did you try this?

Run Equity Valuation Now


Equity Valuation

Check real value of public entities based on technical and fundamental data
All  Next Launch Module
Additionally see Stocks Correlation. Please also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Company logos by clearbit